Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Finished Goods (2016 - 2025)

Historic Finished Goods for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $5.9 million.

  • Harvard Bioscience's Finished Goods rose 2337.96% to $5.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.9 million, marking a year-over-year increase of 2337.96%. This contributed to the annual value of $5.2 million for FY2024, which is 199.22% up from last year.
  • As of Q3 2025, Harvard Bioscience's Finished Goods stood at $5.9 million, which was up 2337.96% from $5.9 million recorded in Q2 2025.
  • Harvard Bioscience's Finished Goods' 5-year high stood at $6.8 million during Q1 2022, with a 5-year trough of $4.8 million in Q3 2024.
  • Moreover, its 5-year median value for Finished Goods was $5.5 million (2024), whereas its average is $5.6 million.
  • In the last 5 years, Harvard Bioscience's Finished Goods soared by 3292.92% in 2022 and then crashed by 2433.07% in 2023.
  • Harvard Bioscience's Finished Goods (Quarter) stood at $5.6 million in 2021, then fell by 7.49% to $5.2 million in 2022, then fell by 1.97% to $5.1 million in 2023, then increased by 1.99% to $5.2 million in 2024, then increased by 12.27% to $5.9 million in 2025.
  • Its last three reported values are $5.9 million in Q3 2025, $5.9 million for Q2 2025, and $5.1 million during Q1 2025.